专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008054121A1 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDES AND ANGIOTENSIN-II-RECEPTOR BLOCKERS 审中-公开
标题翻译：含有THIAZIDES和ANGIOTENSIN-II-受体阻断剂的受控释放的药物组合物
公开(公告)号：WO2008054121A1
公开(公告)日：2008-05-08
申请号：PCT/KR2007/005403
申请日：2007-10-30
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Jin Wook , SON, Jae Woon
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Jin Wook , SON, Jae Woon
IPC分类号： A61K9/22 , A61K31/00 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2086 , A61K9/209 , A61K31/549 , A61K45/06 , A61K2300/00
摘要： Disclosed herein is a pharmaceutical composition, containing a thiazide compound and an angiotensin-II-receptor blocker, and a technology for formulating the same. More particularly, disclosed is a pharmaceutical combination formulation of thiazide compound and angiotensin-II-receptor blocker, which maximizes the pharmacological and clinical antihypertensive effects and complication preventive effects of the drugs and reduces the side effects of the drugs, compared to when single-component formulations of the drugs are administered simultaneously.
摘要翻译：本文公开了含有噻嗪类化合物和血管紧张素-II-受体阻断剂的药物组合物及其制备方法。更具体地，公开了噻嗪类化合物和血管紧张素-II-受体阻断剂的药物组合制剂，其最大化药物的药理学和临床抗高血压作用和并发症预防作用，并降低药物的副作用，与单组分药物的配方同时给药。

2. 发明申请

WO2009048289A2 PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS C VIRUS INFECTION COMPRISING HMG-COA REDUCTASE INHIBITOR AND BILE ACID 审中-公开
标题翻译：用于治疗包含HMG-COA还原酶抑制剂和胆酸的丙型肝炎病毒感染的药物组合物
公开(公告)号：WO2009048289A2
公开(公告)日：2009-04-16
申请号：PCT/KR2008/005965
申请日：2008-10-10
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , LEE, Jun Young
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , LEE, Jun Young
IPC分类号： A61K31/405 , A61K31/23 , A61K31/57 , C07K16/24 , A61P1/16 , A61P31/12
CPC分类号： A61K45/06 , A61K9/209 , A61K31/404 , A61K31/575 , A61K38/21 , A61K2300/00
摘要： Disclosed herein is a pharmaceutical composition for treating hepatitis C virus infection comprising an HMG-CoA reductase inhibitor and bile acid. More specifically, disclosed are a pharmaceutical composition for treating hepatitis C vims infection comprising fluvastatin or a pharmaceutically acceptable salt thereof along with ursodeoxycholic acid and a preparation method thereof.
摘要翻译：本文公开了用于治疗丙型肝炎病毒感染的药物组合物，其包含HMG-CoA还原酶抑制剂和胆汁酸。更具体地，公开了用于治疗丙型肝炎病毒感染的药物组合物及其制备方法，其包含氟伐他汀或其药学上可接受的盐以及熊去氧胆酸。

3. 发明申请

WO2009038396A3 N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 审中-公开
公开(公告)号：WO2009038396A3
公开(公告)日：2009-03-26
申请号：PCT/KR2008/005574
申请日：2008-09-19
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong , KIM, Byoung Ha , KIM, Duck
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong , KIM, Byoung Ha , KIM, Duck
IPC分类号： C07C279/26
摘要： Disclosed herein are a novel dicarboxylic acid salt of N,N- dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N- dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same.

4. 发明申请

WO2009022821A2 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME 审中-公开
标题翻译：包含HMG-COA还原酶和阿司匹林抑制剂的组合制剂及其制造方法
公开(公告)号：WO2009022821A2
公开(公告)日：2009-02-19
申请号：PCT/KR2008/004623
申请日：2008-08-08
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SUN, Sang Ouk
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SUN, Sang Ouk
IPC分类号： A61K31/35
CPC分类号： A61K31/35 , A61K31/616 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs.
摘要翻译：本发明涉及用于预防和治疗心血管疾病的时间治疗组合药物制剂，其基于以特定时间间隔施用多种药物的原理（时间疗法）。具体而言，组合药物制剂包含HMG-CoA还原酶抑制剂，例如辛伐他汀和阿司匹林。由于基于给予药物的原理以一定的时间间隔开发了所谓的时间疗法，所以与单独施用和同时施用单一制剂相比，其显示出预防或治疗心血管疾病的优异效果。此外，这是一种每日一次的剂型，可增加患者的用药依从性。特别是，即使组合药物制剂中阿司匹林的含量降低，阿司匹林在组合药物制剂中的血小板聚集抑制效果等于现有技术中使用的阿司匹林的量，而组合药物中的阿司匹林配方显示出抗高血压作用。此外，时效治疗组合药物制剂允许两种彼此相互作用的药物长时间储存，且组合药物制剂确保两种药物的人体安全性和功效。

5. 发明申请

WO2008093984A1 N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 审中-公开
标题翻译： N，N-二甲基咪唑二羧酸二乙酸酯，其制备方法和包含其的药物组合物
公开(公告)号：WO2008093984A1
公开(公告)日：2008-08-07
申请号：PCT/KR2008/000529
申请日：2008-01-29
申请人： HANALL PHARMACEUTICAL COMPANY. LTD , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong
IPC分类号： A61K31/155
CPC分类号： A61K31/155 , C07C279/26
摘要： The present invention relates to N,N -dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.
摘要翻译：本发明涉及N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其制备方法和包含其的药物组合物，更具体地说，涉及作为结晶酸加成盐的N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其是由使N，N-二甲基亚氨基二亚甲基二酰胺与乙酸反应，作为治疗代谢综合征的糖尿病，糖尿病，肥胖症，高脂血症，脂肪肝，冠心病，骨质疏松症，多囊卵巢综合症，癌症，贫血基因P53等复杂发生; 治疗糖尿病并预防其并发症; 并且由于酸加成盐在溶解性，稳定性，非吸湿性，抗附着性等等的物理化学性质和低毒性方面都是优异的，因此治疗癌症并防止肌肉痛，肌肉细胞毒性和横纹肌溶解等。的制备方法和包含其的药物组合物。

6. 发明申请

WO2008054123A1 CONTROLLED RELEASE COMPLEX COMPOSITION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKERS AND HMG-COA REDUCTASE INHIBITORS 审中-公开
标题翻译：包含血管紧张素II受体阻断剂和HMG-COA还原酶抑制剂的受控释放复合组合物
公开(公告)号：WO2008054123A1
公开(公告)日：2008-05-08
申请号：PCT/KR2007/005405
申请日：2007-10-30
申请人： HANALL PHARMACEUTICAL COMPANY, LTD. , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SON, Jae Woon
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SON, Jae Woon
IPC分类号： A61K9/22 , A61K31/00 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2077 , A61K9/209
摘要： Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.
摘要翻译：本文公开了包含血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂的滞后时间延迟释放组合药物组合物及其制备方法。该组合物是基于治疗时间来设计的，其中施用活性成分具有不同的起始时间，使得组合物的每种活性成分在体内的释放可延迟到特定的速率。此外，该组合物对于治疗高血压和预防具有显示糖尿病，肥胖症，高脂血症，冠状动脉疾病等的代谢综合征的患者的并发症非常有效。更具体地，组合物是药物递送系统，其被设计成使得每种药物的释放被控制到特定的速率，并且当其被吸收在体内时它可以显示出最理想的效果。

7. 发明申请

WO2008023958A1 COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS 审中-公开
标题翻译：具有包含二氢吡啶类钙通道阻断剂和HMG-COA还原酶抑制剂的受控释放的组合药物制剂
公开(公告)号：WO2008023958A1
公开(公告)日：2008-02-28
申请号：PCT/KR2007/004079
申请日：2007-08-24
申请人： HANALL PHARMACEUTICAL CO., LTD. , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja-Seong , KIM, Jin Wook
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja-Seong , KIM, Jin Wook
IPC分类号： A61K9/22 , A61K9/20 , A61K9/52
CPC分类号： A61K9/2866 , A61K9/2077 , A61K9/209 , A61K9/5047 , A61K9/5084
摘要： The present invention relates to a chronotherapeutic combination pharmaceutical formulation, which is designed to control the release of each ingredient of the combined drug in a predetermined rate based on the principle of the so-called chronotherapy, where drugs are administered to exhibit pharmacological activities at predetermined time intervals. The formulation of the present invention comprises a dihydropyridine, calcium channel blocker that affects cytochrome P450 enzyme, and a statin, lipid-lowering agent, as active ingredients. Further, it is prepared in such a manner that the respective release rate of the above ingredients can be controlled, thereby preventing antagonistic effects and side effects resulting from the interaction of the above ingredients, while maintaining the synergistic effect, and providing easy medication.
摘要翻译：本发明涉及一种按时间控制的原理，以预定的速率控制组合药物各成分的释放的时间治疗组合药物制剂，其中给药药物以预定的药物活性显示出时间间隔。本发明的制剂包含影响细胞色素P450酶的二氢吡啶，钙通道阻断剂和作为活性成分的他汀类，降脂剂。此外，其制备方法可以控制上述成分的各自的释放速率，从而防止由于上述成分的相互作用而产生的拮抗作用和副作用，同时保持协同效应，并提供容易的药物。

8. 发明申请

WO2009028900A2 ORAL ADMINISTRATION DRUG COMPRISING CLOPIDOGREL BESYLATE 审中-公开
标题翻译：包含氯吡格雷乙酯的口服给药药物
公开(公告)号：WO2009028900A2
公开(公告)日：2009-03-05
申请号：PCT/KR2008/005079
申请日：2008-08-29
申请人： HANALL PHARMACEUTICAL CO., LTD. , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SUN, Sang Ouk , YU, Jin Hee
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SUN, Sang Ouk , YU, Jin Hee
IPC分类号： A61K9/26 , A61K9/20 , A61K47/00
CPC分类号： A61K9/2054 , A61K9/1611 , A61K9/1623 , A61K9/1652 , A61K9/2009 , A61K9/2018 , A61K9/2059 , A61K9/2095
摘要： The present invention relates to clopidogrel besylate, and more specifically to a pharmaceutical drug for oral administration containing clopidogrel besylate as an active ingredient, which has superior therapeutic effects from the aspects of pharmacokinetics and pharmacodynamics and storage stability while eliminating difficulty in tableting step by wet granulation method adding a binding solution containing a low-grade alcohol during its manufacturing process, and a method of its preparation.
摘要翻译：本发明涉及苯磺酸氯吡格雷，并且更具体地涉及一种含有苯磺酸氯吡格雷作为活性成分的口服药物，其具有从药代动力学和药效学以及储存稳定性方面的优良治疗效果通过在其制造过程中添加含有低级醇的粘合溶液的湿法造粒方法消除了制片步骤中的困难，及其制备方法。

9. 发明申请

WO2008050987A1 COMBINATION FORMULATION WITH CONTROLLED RELEASE COMPRISING METFORMIN AND GLIMEPIRIDE 审中-公开
标题翻译：组合配方与包含甲氟虫和格列美脲的控制释放
公开(公告)号：WO2008050987A1
公开(公告)日：2008-05-02
申请号：PCT/KR2007/005197
申请日：2007-10-23
申请人： HANALL PHARMACEUTICAL CO., LTD. , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja-Seong , JUN, Yoon-Sik
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja-Seong , JUN, Yoon-Sik
IPC分类号： A61K9/24 , A61K9/22 , A61K31/155 , A61P3/10
CPC分类号： A61K31/155 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/209 , A61K31/64 , A61K2300/00
摘要： The present invention relates to a controlled-release metformin-glimepiride combination formulation, and particularly to a controlled-release metformin- glimepiride combination formulation for oral administration, where a controlled- release layer is constructed so that the release of metformin having high water solubility and high unit dose may be maintained for 24 hours by selectively designing a release-controlling material and an immediate-release layer is constructed so that the content of glimepiride having low water solubility and low unit dose may be maintained uniform and it may also be immediately released. In particular, a controlled-release metformin-glimepiride combination formulation herein may be embodied into a multi-layered tablet, where a controlled-release layer and an immediate-release layer are separated to completely separate metformin and glimepiride so that excipients constructing the controlled-release layer may not affect an rapid release of glimepiride, thereby minimizing the interaction of drugs and maintaining the complementary activities of the drugs, thus being efficacious for especially type 2 diabetes.
摘要翻译：本发明涉及一种控制释放的二甲双胍 - 格列美脲组合制剂，特别涉及用于口服给药的控释二甲双胍 - 格列美脲组合制剂，其中构建控释层，使得具有高水溶性的二甲双胍的释放和通过选择性地设计释放控制材料，可以保持高单位剂量24小时，并且构建即释释层，使得具有低水溶性和低单位剂量的格列美脲的含量可以保持均匀并且还可以立即释放。特别地，本文的控释二甲双胍 - 格列美脲组合制剂可以实施成多层片剂，其中将分解层和速释层分离成完全分离二甲双胍和格列美脲，释放层可能不会影响格列美脲的快速释放，从而最小化药物的相互作用并维持药物的互补活性，从而对特别是2型糖尿病有效。

10. 发明申请

WO2008044862A1 COMBINED PREPARATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THEORY 审中-公开
标题翻译：基于循环理论治疗心血管疾病的联合制剂
公开(公告)号：WO2008044862A1
公开(公告)日：2008-04-17
申请号：PCT/KR2007/004929
申请日：2007-10-10
申请人： HANALL PHARMACEUTICAL CO., LTD. , KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja-Seong , SUN, Sang Ouk
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja-Seong , SUN, Sang Ouk
IPC分类号： A61K9/22 , A61K31/4184 , A61K9/12 , A61P9/12
CPC分类号： A61K31/4184 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/209 , A61K9/2853 , A61K9/2866 , A61K9/5084 , A61K31/4178 , A61K31/4422 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a functional combination preparation comprising a dihydropyridine-based calcium channel blocker such as amlodipine and an ARB (Angiotensin-2 receptor blocker) such as losartan. In particular, the present invention relates to a chronotherapeutical combination pharmaceutical formulations with controlled-release for the prevention or treatment of cardiovascular disease, which is formulated in accordance with xenobiotics and chronotherapy for enabling the two drugs to be chronotherapeutically released, thereby improving the therapeutic activity as compared to the co-administration of each drug in the form of a single pill, while reducing side effects and maintaining the therapeutic activity as high as possible at the time of day when the risk of a complication of cardiovascular disease is highest.
摘要翻译：本发明涉及包含二氢吡啶类钙通道阻断剂如氨氯地平和ARB（血管紧张素-2受体阻断剂）如洛沙坦的功能性组合制剂。特别地，本发明涉及具有控制释放以用于预防或治疗心血管疾病的时间疗法组合药物制剂，所述药物制剂根据异生素和时间疗法配制，以使两种药物能够进行治疗性释放，从而改善治疗活性与单一药丸形式的每种药物的共同给药相比，同时在心血管疾病并发症的风险最高的一天中减少副作用并保持尽可能高的治疗活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式